Can Moderna Thrive Beyond COVID-19 Amid Regulatory Shake-Ups?
Moderna is transitioning from its COVID-19 success to a broader biotech focus, aiming to innovate in areas like cancer and rare diseases. The company's stock has dropped 74% after previously…